August 30, 2023

Nemolizumab has a rapid onset of action in prurigo nodularis, as represented by improvement in sleep and itch reduction within 48 hours of administration. Individuals with prurigo nodularis tend to experience multiple itchy nodules, sleep disturbances, and a poor quality of life. Nemolizumab is an interleukin 31 α receptor (IL-31AR) inhibitor that positively affects prurigo...

Treatment of prurigo nodularis patients with dupilumab produced statistically significant improvement in skin lesions and pruritus, according to a review of two clinical trials. Prurigo nodularis is characterized by chronic inflammation of the skin and the development of intensely pruritic nodules. There is inadequate evidence regarding the safety profile and treatment efficacy of dupilumab in...

A recent review confirmed the clinical effectiveness of dupilumab for treating prurigo nodularis, as represented by significant decreases in numeric rating scale itch intensity scores and high safety ratings in prurigo nodularis patients with no serious adverse events. The conventional therapeutic approaches in the management of prurigo nodularis have high side effect profiles and limited...

Compared to treatment with a placebo, patients with moderate to severe prurigo nodularis treated with nemolizumab demonstrated modulation of epithelial differentiation, inflammatory signaling, and neural development. Prurigo nodularis is a dermatological condition that involves hyperkeratotic skin nodules and intense pruritus. Nemolizumab is a monoclonal interleukin 31 receptor α antibody that represents a novel therapeutic strategy...

A recent study found that patients with prurigo nodularis had relatively greater abnormalities identified on metabolic, renal, hepatic, hematologic, and endocrine laboratory testing compared to healthy controls.  Prurigo nodularis is a chronic dermatological condition that is associated with different systemic comorbidities. The current medical literature lacks adequate evidence to support laboratory testing in the diagnosis...

Sickle cell disease is known to be associated with worse pregnancy outcomes and higher maternal mortality. However, a new study shows that racial disparities significantly contribute to adverse pregnancy outcomes in Black women. Sickle cell disease (SCD) is more likely to affect people of African descent. Additionally, it is known that SCD significantly increases the...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on Oct. 4, 2023 A new study finds that Black patients have a lower life expectancy when living with sickle cell disease compared to Non-Blacks. This is despite being insured by Medicare and Medicaid, and might point to healthcare disparities requiring further investigation. Sickle Cell Disease (SCD) affects about...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on Oct. 5, 2023 A new study shows a significant difference in RSV-related mortality between high- and low-income population groups, which is primarily due to prevalent health disparities globally. Respiratory syncytial virus (RSV) is among the most significant causes of acute lower respiratory tract infection (ALRI) in children below...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on Oct. 4, 2023 RSV causes disproportionate morbidity and mortality in vulnerable populations. A study in Seattle, Washington, found that residents of homeless shelters are more likely to suffer from severe RSV infections and to have co-infections with other respiratory viruses. Respiratory syncytial virus (RSV) is among the leading...